Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bilin Weitong granules (比林胃痛颗粒) is a traditional Chinese medicine (TCM) product developed by Yangtze River Pharmaceutical Group (specifically its subsidiaries Jiangsu Pharmaceutical and Jiangsu Longfengtang Traditional Chinese Medicine). It is currently in Phase III clinical development in China for the treatment of functional dyspepsia, specifically the epigastric pain syndrome (EPS) subtype. The formulation is indicated for patients presenting with the TCM pattern of qi stagnation and blood stasis. The therapeutic approach focuses on regulating qi and resolving blood stasis to alleviate chronic epigastric pain and discomfort associated with functional dyspepsia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bilin Weitong granules.